We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Urine Test Helps Diagnose Bladder Cancer

By LabMedica International staff writers
Posted on 22 Dec 2015
Print article
Image: The minichromosome maintenance complex component 5 (Mcm5)-enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of Arquer Diagnostics Ltd.).
Image: The minichromosome maintenance complex component 5 (Mcm5)-enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of Arquer Diagnostics Ltd.).
Bladder cancer is the seventh most common type in the UK, with around 10,000 people diagnosed every year and around two-thirds of cases recur within five years, so patients are monitored routinely after treatment.

Patients with bladder cancer are currently tested and monitored via an invasive cystoscopy examination, which involves passing a thin device through the urethra, the tube which carries urine out of the body, to examine the inside of the bladder.

Clinicians at Southampton General Hospital (UK) are set to lead a pioneering UK study into the use of a urine test that could help to diagnose bladder cancer. The team will recruit around 40 patients who have been diagnosed with the disease to participate in the trial. They will take urine samples from patients before treatment begins and at every follow-up appointment over a six-month period.

The test works by detecting a protein known as minichromosome maintenance complex component 5 (MCM5), which is shed into urine by bladder and prostate tumors. The MCM5- enzyme-linked immunosorbent assay (ELISA) was developed by Arquer Diagnostics Ltd. (Sunderland, UK). A recent successful screening trial involving 350 hematuria patients indicated that the MCM5-ELISA test has a sensitivity of 83%, a specificity of 77% and negative predictive value of 98%.

Tim Dudderidge, MB ChB, MSc, FRCS, the principal investigator, said, “There is currently an unmet need for a test that would allow for more screening and enable earlier detection of bladder cancer. At present, patients are referred to hospital to undergo a cystoscopy examination which involves using local anesthetic and can be very uncomfortable for patients. The MCM5-ELISA test has the potential to provide patients with a simple and noninvasive solution for screening and for the detection of recurrence for the first time and we are pleased to be part of such an exciting development.”

Related Links:

Southampton General Hospital 
Arquer Diagnostics Ltd. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.